Efficacy of Radiofrequency Ablation Combined With Endoscopic Resection for Barrett s Esophagus With Early Neoplasia
|
|
- Hester Thornton
- 6 years ago
- Views:
Transcription
1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:23 29 ENDOSCOPY CORNER Efficacy of Radiofrequency Ablation Combined With Endoscopic Resection for Barrett s Esophagus With Early Neoplasia ROOS E. POUW,* KATJA WIRTHS, PIERRE EISENDRATH, CARINE M. SONDERMEIJER,* FIEBO J. TEN KATE, PAUL FOCKENS,* JACQUES DEVIÈRE, HORST NEUHAUS, and JACQUES J. BERGMAN* *Department of Gastroenterology and Hepatology, Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Internal Medicine, Evangelisches Krankenhaus, Düsseldorf, Germany; and the Department of Gastroenterology and Hepatopancreatology, Erasme University Hospital, Brussels, Belgium See Editorial on page 7. BACKGROUND & AIMS: Radiofrequency ablation (RFA) is safe and effective for eradicating intestinal metaplasia and neoplasia in patients with Barrett s esophagus. We sought to assess the safety and efficacy of RFA in conjunction with baseline endoscopic resection for high-grade intraepithelial neoplasia (HGIN) and early cancer. METHODS: This multicenter, prospective cohort study included 24 patients (mean age, 65 years; median Barrett s esophagus, 8 cm), with Barrett s esophagus of 12 cm containing HGIN or early cancer, from 3 European tertiary-care medical centers. Visible lesions were endoscopically resected, followed by serial RFA. Focal escape endoscopic resection was used if Barrett tissue persisted despite RFA. Complete response, defined as all biopsies negative for intestinal metaplasia and neoplasia, was assessed during endoscopy with 4-quadrant biopsies taken every 1 cm of the original Barrett s segment 2 months after the patient was last treated. RESULTS: Twenty-three patients underwent pre-rfa endoscopic resection for visible lesions; 16 patients had early cancer and 7 patients had HGIN. The worst residual histology results, pre-rfa (after any endoscopic resection) were: HGIN (10 patients), low-grade intraepithelial neoplasia (11 patients), and intestinal metaplasia (3 patients). Neoplasia and intestinal metaplasia were eradicated in 95% and 88% of patients, respectively; after escape endoscopic resection in 2 patients, rates improved to 100% and 96%, respectively. Complications after RFA included melena (n 1) and dysphagia (n 1). After additional follow-up (median, 22 months; interquartile range, months) no neoplasia recurred. CONCLU- SIONS: This European multicenter study to show that early neoplasia in Barrett s esophagus can be effectively and safely treated with RFA, in combination with prior endoscopic resection of visible lesions. Barrett s esophagus (BE), defined as a columnar-lined esophagus and biopsy showing specialized intestinal metaplasia (IM), is the most important risk factor for the development of esophageal adenocarcinoma. 1 Patients with known BE undergo endoscopic surveillance to detect neoplasia (ie, highgrade intraepithelial neoplasia [HGIN] or early cancer [EC]) at a curable stage. 2 Patients with HGIN or with EC confined to the mucosa (T1m) may be treated endoscopically owing to low risk for lymph node metastasis at the time of diagnosis, but more advanced cancers are surgical indications. 3 8 The cornerstone of endoscopic treatment of early BE neoplasia is endoscopic resection (ER), which allows for removal of visible lesions and assessment of tumor infiltration depth and differentiation. After focal ER, however, the residual Barrett s mucosa remains at risk for malignant transformation, and cancer recurrences are found in 30% of patients during follow-up evaluation. 3,4 To prevent such metachronous lesions, endoscopic approaches have been studied in an attempt to eradicate the residual Barrett s mucosa (eg, radical ER, 9,10 photodynamic therapy, and argon plasma coagulation) These treatment options, however, do not always result in complete clearance of IM and associated intraepithelial neoplasia and are limited by other shortcomings such as esophageal stenosis, photosensitivity, and subsquamous foci of IM (also known as buried Barrett s) A newer endoscopic ablation technique is radiofrequency ablation (RFA), which has promising safety and efficacy results published for nondysplastic BE, 20,21 low-grade intraepithelial neoplasia (LGIN), 22,23 and HGIN Single-center studies effectively have combined focal ER of visible lesions with RFA for residual Barrett s mucosa in patients with HGIN and EC. 24,25 The aim of the present study was to evaluate further the safety and efficacy of this combined modality approach in BE patients with HGIN or EC in a European multicenter setting. Materials and Methods Study Design This was a prospective cohort trial conducted at 3 tertiary-care medical centers in Europe. The ethical committee of each institution reviewed and approved the protocol and the Abbreviations used in this paper: BE, Barrett s esophagus; CR-IM, complete response for intestinal metaplasia; CR-neoplasia, complete response for neoplasia; EC, early cancer; ER, endoscopic resection; HGIN, high-grade intraepithelial neoplasia; IM, intestinal metaplasia; IQR, interquartile range; LGIN, low-grade intraepithelial neoplasia; NBI, narrow-band imaging; RFA, radiofrequency ablation by the AGA Institute /10/$36.00 doi: /j.cgh
2 24 POUW ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 1 patient informed consent form. The trial was registered at (NTR1434). A central study coordinator monitored all procedures and entered data into a central database. Patients were eligible if they met all inclusion criteria as follows: age 18 to 85 years, BE length of 12 cm or less, HGIN or EC in BE segment on 2 endoscopies in the prior 6 months, visible lesions removed with ER before RFA, and no signs of metastasis on endoscopic ultrasonography or computed tomography scan. Patients were excluded if they met any exclusion criterion: pre-rfa ER with cancer at the vertical resection margin, greater than T1sm1 invasion, poor differentiation or worse, or angiolymphatic invasion; esophageal stenosis preventing passage of an 11.3-mm endoscope; persistent visible lesions after ER and pre-rfa; invasive cancer on biopsies after ER and pre-rfa. To ascertain eligibility, patients underwent 2 high-resolution endoscopies with documentation of BE landmarks according to the Prague classification system. 26 In the case of visible lesions, these were removed with ER followed by 2 additional endoscopies with 4-quadrant 1-cm biopsies to exclude residual cancer and residual nonflat lesions. Endoscopic ultrasonography was performed in all patients to rule out exclusionary lesions. In the case of cancer on biopsy or ER, a computed tomography scan of the thorax and upper one third of the abdomen was performed to rule out metastatic disease. Endoscopic Interventions All procedures were performed on an outpatient basis using intravenous midazolam, fentanyl, pethidine, propofol, or a combination thereof. All patients were prescribed high-dose proton pump inhibitor therapy (esomeprazole 40 mg twice a day) during the entire study period, supplemented with sucralfate suspension 5 ml (200 mg/ml) 4 times a day and ranitidine 300 mg before bedtime for 2 weeks after any therapeutic endoscopy. ER of any nonflat lesions was performed using the ER-cap technique, the multiband mucosectomy technique, or endoscopic submucosal dissection, at the discretion of the physician. The HALO 360 and HALO 90 ablation systems used in this trial have 510(k) clearance by the Food and Drug Administration in the United States and the CE Mark for Europe for the treatment of BE (BÂRRX Medical Inc, Sunnyvale, CA). For circumferential RFA, a sizing catheter was introduced over a guidewire to measure the inner-esophageal diameter of the esophagus. A HALO 360 ablation catheter of appropriate outer diameter was introduced over the guidewire followed by the endoscope in a side-by-side manner. The electrode was positioned 1 cm above the proximal extent of the BE, the balloon was inflated, and energy was delivered (12 J/cm 2,40 W/cm 2 ), resulting in circumferential ablation of a 3-cm segment. The ablation catheter was repositioned distal to the prior ablation zone, allowing minimal overlap, and ablation was repeated until the entire BE was ablated. The ablation catheter was removed to clean the electrode surface, while a soft distal attachment cap (model MB-046; Olympus, Tokyo, Japan) was mounted on the endoscope and used to clean the ablation zone. Residual debris then was removed by forceful spraying of water through a spraying catheter with a pressure pistol (Alliance; Boston Scientific, Limerick, Ireland). After cleaning, the ablation catheter was re-introduced and the BE segment was treated a second time. For secondary focal ablation, each island or tongue of residual Barrett s mucosa was aligned with the focal HALO 90 catheter, the endoscope was deflected to bring the electrode into contact, and RF energy was delivered twice in succession (15 J/cm 2, 40 W/cm 2 ). All areas were cleaned by pushing the coagulum off with the leading edge of the device. The electrode was removed to clean its surface, and then re-introduced to re-treat all areas twice more in succession. In all patients, the gastroesophageal junction was treated circumferentially with the HALO 90 catheter at least once (2 2, 15 J/cm 2 ), to ensure eradication of IM at this level. Patient Flow Baseline visible lesions were removed by ER, followed by primary RFA at least 6 weeks after the ER and within 3 months after the last biopsy session. Additional RFA sessions were scheduled every 8 weeks thereafter until complete endoscopic eradication was achieved. A maximum of 2 circumferential and 3 focal RFA sessions was allowed. Any residual Barrett s epithelium persisting after the maximum number of allowable RFA sessions was removed with a focal ER as escape therapy. Two months after the last treatment session the original extent of BE was biopsied every 1 cm, including immediately ( 5 mm) distal to the neosquamocolumnar junction. If patients had reached complete resolution of intestinal metaplasia and complete resolution of neoplasia they were scheduled for follow-up endoscopy and 4-quadrant biopsies at 6 and 12 months after the last treatment session, and annually thereafter (Figure 1). Outcome Variables The primary end points were histology-based (biopsy specimens obtained 2 months after the last therapeutic intervention). A complete response was defined as all biopsies negative for IM (complete response [CR]-IM) and neoplasia (CRneoplasia), reported separately. Secondary end points were as follows: disease progression, adverse events, and durability of CR-IM and CR-neoplasia at the last biopsy available. Histologic Analysis All ER specimens and biopsy specimens from baseline and follow-up evaluation were evaluated by the central study pathologist (F.J.t.K.), an expert in gastrointestinal pathology. ER specimens were evaluated for neoplasia according to the World Health Organization classification, 27 tumor infiltration depth, differentiation, presence of lymphatic or vascular infiltration, and completeness of resection at the vertical margin. Biopsy specimens were evaluated for the presence of IM, LGIN, HGIN, and EC, and follow-up biopsy specimens from the neosquamous epithelium were evaluated for the presence of subsquamous areas of IM. Statistical Analysis Statistical analysis was performed with SPSS software for Windows (SPSS Inc, Chicago, IL). For descriptive statistics, mean ( standard deviation) was used in case of a normal distribution of variables, and median (interquartile range [IQR]) was used for variables with a skewed distribution.
3 January 2010 ABLATION OF NEOPLASTIC BARRETT S ESOPHAGUS 25 Figure 1. Flow-chart of the study protocol. ND-BE, nondysplastic Barrett s esophagus; EGD, esophagogastroduodenoscopy. Where appropriate, the Student t test and the Mann Whitney test were used. Results Enrollment and Baseline Characteristics Twenty-four patients were included (20 men; mean age, y; median BE length, C6M8; IQR, C2 9, M4 10). Twenty patients had a hiatal hernia (median, 2 cm; IQR, 2 3). Sixteen patients had a baseline diagnosis of cancer; 8 patients had HGIN as the worst histologic finding at 2 work-up endoscopies. Baseline Endoscopic Resection Twenty-three patients (96%) underwent a total of 25 ER sessions before RFA (2 patients had 2 ER sessions). Of the 25
4 26 POUW ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 1 ER sessions, 12 were performed with the ER-cap technique, 12 with the multiband mucosectomy technique, and 1 with endoscopic submucosal dissection. The worst histologic grade based on ER was EC in 16 patients (T1m2, n 8; T1m3, n 6; and T1sm1, n 2) and HGIN in 7 patients. The worst grade of residual intraepithelial neoplasia in biopsy specimens obtained from the remaining BE during at least 2 high-resolution endoscopies after any ER was HGIN in 10 patients (in the absence of any visible lesions), LGIN in 11 patients, and 3 patients had IM without neoplasia. Number of Treatment Sessions Patients underwent a median of 1 (IQR, 1 1) primary circumferential and 1 (IQR, 1 2) secondary focal RFA session. Escape ER was necessary in 1 patient to remove a resistant 8-mm Barrett s island (LGIN). Escape ER was necessary in a second patient to remove 4 small BE foci (IM, no neoplasia) because of difficulty in introducing the focal RFA device. Overall, patients required a median number of 3 (IQR, 3 4) therapeutic interventions (including any ER before and after RFA), during a median period of 6.4 months (IQR, mo). Primary Outcome Variables Eradication of intraepithelial neoplasia and intestinal metaplasia. In 20 of 21 patients with residual LGIN/ HGIN in their BE after ER and before ablation, CR-neoplasia was achieved with RFA (95%). Escape ER for an 8-mm island of LGIN resulted in CR-neoplasia in all 21 patients (100%). CR-IM was achieved with RFA in 21 of 24 patients (88%). After escape ER in 2 patients (see earlier), CR-IM was reached in 23 of 24 patients (96%). The single patient in whom CR-IM was not achieved had a C10M10 nonneoplastic Barrett s segment after ER of a T1m2 carcinoma at baseline and did not regenerate neosquamous epithelium readily after RFA. Thus, he was removed from the trial. Secondary Outcome Variables Progression. During the follow-up period, there were no new cancers and no histologic progression of disease. Adverse events. Endoscopic resection related complications. One severe complication, an esophageal perforation, occurred after baseline ER (cap technique), and was treated nonsurgically with clips and a covered stent. This patient underwent a second ER session 3 months after the perforation and went on to have RFA 2 months after the second ER, without further complication, and is now CR-IM at 2, 6, and 12 months. Radiofrequency ablation related complications. No severe complications occurred after RFA. Two complications (8%) were graded as being of moderate severity because they required additional endoscopic procedures: 1 patient presented with melena 2 weeks after focal ablation. At endoscopic inspection no active bleeding was observed, but 2 visible vessels in the ablated area were clipped preventively. A second patient developed dysphagia after the first RFA. He had undergone widespread ER before RFA and had a mucosal laceration after circumferential RFA. The stenosis was resolved with 5 endoscopic dilatation sessions, after which ablation treatment could be resumed. Mucosal laceration was observed in 5 patients (21%) after circumferential RFA, all occurring within the mucosal scar region of a prior ER (Figure 2). All patients remained asymptomatic and no therapeutic interventions were required. These lacerations therefore were graded as mild complications. Durability of complete response. After a median follow-up period of 22 months (IQR, mo) after the last treatment, and a median of 3 follow-up endoscopies (IQR, 3 4) per patient, no recurrence of neoplasia was observed. Long-term complete response for IM was maintained in 20 of 24 included patients (83%). In one patient with baseline C9M10 and CR-neoplasia and CR-IM at 2 months, a tiny (0.5 3 mm) glandular island with IM at biopsy was found at the 6-month follow-up endoscopy. The island was located distal to a reflux stenosis and was detected only after inspection with narrow-band imaging (NBI) (Figure 3). In 2 patients at 6 months, focal nonneoplastic IM was found in one biopsy each, obtained distal to the gastroesophageal junction. In neither patient was this finding reproduced at 12 months. No buried Barrett s was found in a total of 1201 neosquamous biopsy specimens obtained during the follow-up evaluation. Discussion There is no generally accepted management strategy for patients with early neoplasia in BE. However, studies in which focal ER for neoplasia was followed by surveillance of residual BE have reported a 20% to 30% rate of metachronous lesions, 3 5 whereas studies in which the whole BE was eradicated after focal ER only reported recurrence in up to 6% of patients Based on these data, we believe that combining ER with complete ablation of residual Barrett s mucosa is the preferable treatment approach, and in this multicenter European trial we therefore evaluated RFA in conjunction with ER for the treatment of BE containing neoplasia and early cancer. The primary end point of complete eradication of all residual neoplasia after ER was achieved in 21 of 21 patients (CR-neoplasia, 100%). The primary end point of complete eradication of all residual IM after ER was achieved in 23 of 24 patients (CR-IM, 96%). These results comport with those from 2 recently published, singlecenter studies in which RFA was used in conjunction with ER for HGIN and EC to achieve 100% CR-IM and 100% CRneoplasia. 24,25 These favorable outcomes collectively endorse a central role for RFA in the treatment of patients with flat-type neoplasia in a BE. All but one patient in this study underwent baseline ER for visible lesions. This emphasizes that in our opinion ER should be performed not only for nodules, but for any mucosal irregularity or area with suspicious glandular patterns no matter how subtle, even if prior biopsies do not show cancer but HGIN or lower. Not only is baseline ER important to render the mucosa flat for subsequent ablation, but it provides an adequate specimen for histopathologic analysis and has been shown to change the histologic diagnosis on the basis of prior biopsies in 49% of patients. 28 Such a rigorous baseline evaluation is of the utmost importance to enable selection of patients who are eligible for further endoscopic treatment with RFA, that is, patients without deep submucosal invading cancer ( T1sm1), or poorly differentiated cancer, versus those who require surgical intervention. In the case of minimal submucosal infiltration (T1sm1), recent studies have suggested that the risk of lymph node metastasis is very low. 8,29 Two patients had minimal submucosal invasion diagnosed in the ER specimen. Because of the absence of other risk factors for lymph node
5 January 2010 ABLATION OF NEOPLASTIC BARRETT S ESOPHAGUS 27 Figure 2. Endoscopic images of circumferential RFA, complicated by nontransmural mucosal laceration. (A) C11M12 BE. (B) At 32 cm from the incisors a suspicious lesion was observed. (C) The lesion was removed in 2 pieces using multiband mucosectomy. Histology showed HGIN. (D) Before circumferential RFA, 6 weeks after ER, esophageal scarring was observed at the resection site. (E and F) During circumferential RFA, inflation of the balloon catheter caused nontransmural mucosal laceration, probably because of overstretching at the level of the ER scar. (G) Three months after primary circumferential RFA, 2 residual islands of Barrett s mucosa were detected with NBI. (H) The islands were treated with focal RFA. (I L) Two months after the last ablation, complete endoscopic eradication of neoplasia and IM was reached, and the esophagus was covered with normal-appearing neosquamous epithelium, as seen with white-light endoscopy and NBI. metastasis (poor differentiation grade, irradical resection, lymphatic/vascular infiltration), surgical as well as endoscopic treatment options were discussed elaborately with the patients, and both decided to be treated endoscopically within the study protocol. In a prior clinical study, 24 we allowed only single-piece baseline ER before RFA. In a subsequent study, 25 we relaxed this restriction to allow multiple-piece ER (median, 2 specimens; IQR, 2 3 specimens) before RFA. No mucosal lacerations occurred and a stricture occurred in only one patient after 2 ER sessions and RFA. In the present study, based partially on prior results, we did not initially restrict the extent of baseline ER. During the first half of this study, we noted 5 mucosal laceration events within the ER scar zone during circumferential RFA and one stenosis; and we related this to extensive baseline ER and scarring (Figure 2). None of the lacerations required intervention or caused complaints, therefore they were regarded as mild complications. However, because lacerations may provoke severe bleeding or esophageal perforation, the investigator group added a restriction to the baseline extent of ER (maximum 50% of circumference; 2-cm length, and 1 session). We also used a more conservative approach in selecting an ablation catheter balloon size, erring on the small size. After this modification, no further lacerations or stenoses were observed. One patient was removed from the trial and considered a failure because of poor healing of the esophagus after circumferential RFA. At baseline, the patient had an EC resected with ER, leaving a residual C10M10 Barrett s segment with no neoplasia. The patient previously had undergone a Nissen fundoplication and postoperative 24-hour ph-metry was normal off proton pump inhibitor treatment. Yet, despite a maximum acid-suppressant regimen (esomeprazole 80 mg twice a day, ranitidine 300 mg at bedtime, sucralfate 5 ml 4 times/d) the esophagus failed to regenerate readily with neosquamous epithelium. It is unclear what factors were at play in this particular patient s poor healing, but it highlights the fact that tailored management may be necessary in some cases. In 3 patients (83%) with complete eradication of IM and neoplasia, IM was found in biopsy specimens during the follow-up evaluation, which raises the question of whether endoscopic surveillance will remain necessary after complete eradication of IM and neoplasia has been reached. Currently, endoscopic follow-up evaluation after successful eradication of BE by RFA is recommended at regular intervals based on base-
6 28 POUW ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 1 Figure 3. Endoscopic images of a small island of glandular mucosa detected during the follow-up evaluation. (A and B) C9M10 BE with proximal reflux stenosis, containing diffuse HGIN after ER for early cancer. (C and D) Residual Barrett s mucosa was converted completely to neosquamous mucosa by 1 circumferential and 1 focal RFA. No recurrence of neoplasia or IM was found at the 2-month follow-up evaluation. (E and F) At the 6-month follow-up evaluation, however, NBI revealed a tiny island of columnar epithelium just distal to the reflux stenosis and the biopsy showed IM. line histologic diagnosis because no long-term follow-up data are as yet available. In two thirds of patients with IM during the follow-up evaluation, focal nondysplastic IM was found in a single biopsy just distal to the neosquamocolumnar junction at a single follow-up endoscopy and in neither patient was this finding reproduced during following endoscopies. Because all patients had an initial diagnosis of HGIN/EC, one may argue that residual IM in the cardia reflects incomplete cure of the underlying disease. However, IM of the cardia can be detected in up to 25% of patients with a normal-appearing squamocolumnar junction and is not considered premalignant in those cases. 30 The clinical relevance of this finding is thus unclear, but in our opinion nondysplastic IM in biopsies distal to the neosquamocolumnar junction do not require additional treatment, whereas IM with LGIN or HGIN should be treated. However, long-term follow-up data of these patients may clarify how focal IM in the cardia will behave after RFA. One patient had a mm island of columnar epithelium detected, with IM at biopsy, during the follow-up endoscopy at 6 months, despite being CR-IM at 2 months. The island was observed only after inspection with NBI (Figure 3). We hypothesize that we missed this island visually on prior follow-up endoscopy because of its limited size and position just distal to a reflux stenosis. It is in our opinion therefore recommended to use high-resolution endoscopy, NBI, Lugol s chromoendoscopy, or comparable techniques during follow-up evaluation after RFA to exclude the presence of residual BE tissue, especially small islands. As described in this article, the selection of patients for endoscopic treatment involves a thorough endoscopic work-up, the possibility to perform ER safely, and accurate histologic evaluation of tissue specimens for the presence of risk factors for lymph node metastasis. 31 Because all patients in this study underwent endoscopic work-up and RFA in specialized tertiarycare centers, the high reported safety and efficacy should be extrapolated to general practice with care. In our opinion, it may be advisable to centralize RFA of BE patients with HGIN/EC in centers with multidisciplinary experience in this field (ie, expertise with endoscopic imaging and ER, access to esophageal surgery, expert gastrointestinal histopathology) and that have participated in dedicated RFA training courses at expert centers. One strength of this study was the use of a single expert gastrointestinal pathologist for all specimen reviews. Other strengths included the multicenter design, use of baseline ER for histologic staging, post-er and pre-rfa biopsy regimen to elucidate the post-er diagnosis, observation of all RFA procedures and primary end point biopsy procedures by the central study monitor to ensure protocol adherence, and patient follow-up evaluation that extended a median of 22 months beyond the last therapeutic intervention. One weakness of this study was that many of the baseline ER procedures were performed before patient enrollment during confirmation of eligibility, and therefore were not supervised by the study coordinator. However, all centers used standardized techniques and data collection, and all ER specimens were reviewed by the study pathologist. Also, we allowed focal escape ER in certain rare circumstances, which could bias our outcomes favorably. Furthermore, midway through the study we necessarily adjusted the extent of permissible baseline ER. This restriction appears to be associated with a lower risk of complications (namely, mucosal laceration), but more patients are needed to make this determination. Lastly, a relatively small number of patients were included in this study and treated in 3 expert centers. We therefore initiated a second multicenter study in 12 European centers that uses the inclusion criteria defined in this study and aims at including a minimum of 100 patients. The results of this European multicenter study show that patients with early neoplasia arising in BE can be treated effectively and safely with RFA, in combination with prior ER of visible lesions. References 1. Hameeteman W, Tytgat GN, Houthoff HJ, et al. Barrett s esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96: Enzinger PC, Mayer RJ. Medical progress: esophageal cancer. N Engl J Med 2003;349: Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett s esophagus. Gastrointest Endosc 2005;61: May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett s oesophagus: acute-phase and intermediate results of a
7 January 2010 ABLATION OF NEOPLASTIC BARRETT S ESOPHAGUS 29 new treatment approach. Eur J Gastroenterol Hepatol 2002;14: Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett s oesophagus. Gut 2008;57: Bollschweiler E, Baldus SE, Schröder W, et al. High rate of lymph-node metastasis in submucosal esophageal squamouscell carcinomas and adenocarcinomas. Endoscopy 2006;38: Buskens CJ, Westerterp M, Lagarde SM, et al. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004;60: Westerterp M, Koppert LB, Buskens CJ, et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastroesophageal junction. Virchows Arch 2005;446: Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett s esophagus with early neoplasia: a prospective study. Am J Gastroenterol 2006;101: Seewald S, Akaraviputh T, Seitz U, et al. Circumferential EMR and complete removal of Barrett s epithelium: a new approach to management of Barrett s esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003;57: Buttar NS, Wang KK, Lutzke LS, et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett s esophagus. Gastrointest Endosc 2001; 54: Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett s esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003;58: Peters F, Kara M, Rosmolen W, et al. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in Barrett esophagus after endoscopic resection. Endoscopy 2005;37: Sharma P, Wani S, Weston AP, et al. A randomised controlled trial of ablation of Barrett s oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut 2006;55: Van Laethem JL, Jagodzinski R, Peny MO, et al. Argon plasma coagulation in the treatment of Barrett s high-grade dysplasia and in situ adenocarcinoma. Endoscopy 2001;33: Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett s epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc 2000;51: Ganz RA, Utley DS, Stern RA, et al. Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: a phased evaluation in the porcine and in the human esophagus. Gastrointest Endosc 2004;60: Dunkin BJ, Martinez J, Bejarano PA, et al. Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device. Surg Endosc 2006;20: Smith CD, Bejarano PA, Melvin WS, et al. Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system. Surg Endosc 2007;21: Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett s esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007;65: Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett s esophagus: a multicenter study with 2.5-year followup. Gastrointest Endosc 2008;68: Sharma VK, Kim HJ, Das A, et al. A prospective pilot trial of ablation of Barrett s esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy 2008;40: Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett s esophagus with dysplasia. N Engl J Med 2009; 360: Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Stepwise circumferential and focal ablation of Barrett s esophagus with highgrade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008;40: Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008;40: Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett s esophagus: the Prague C& M criteria. Gastroenterology 2006;131: Hamilton SR, Aaltonen LA, eds. WHO classification. Tumours of the digestive system. Lyon: IARC Press, Peters FP, Brakenhoff KP, Curvers WL, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett s esophagus. Gastrointest Endosc 2008;67: Manner H, May A, Pech O, et al. Early Barrett s carcinoma with low-risk submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol 2008;103: Morales TG, Camargo E, Bhattacharyya A, et al. Long-term follow-up of intestinal metaplasia of the gastric cardia. Am J Gastroenterol 2000;95: Pouw RE, Sharma VK, Bergman JJ, et al. Radiofrequency ablation for total Barrett s eradication: a description of the endoscopic technique, its clinical results and future prospects. Endoscopy 2008;40: Reprint requests Address requests for reprints to: Jacques J. Bergman, MD, PhD, Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. j.j.bergman@amc.uva.nl; fax: (31) Conflicts of interest The authors disclose the following: Roos Pouw is supported by an unrestricted research grant from AstraZeneca BV (The Netherlands); Jacques Bergman has received research support in the form of grants and materials for conducting studies from BÂRRX Medical (Sunnyvale, CA), AstraZeneca BV (The Netherlands), and Olympus Endoscopy (Tokyo, Japan). The remaining authors disclose no conflicts.
Citation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic management of Barrett s esophagus with dysplasia
UvA-DARE (Digital Academic Repository) Endoscopic management of Barrett s esophagus with dysplasia Phoa, Nadine Link to publication Citation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic
More informationRadiofrequency Ablation: Stepwise circumferential and focal RFA of Barrett s s esophagus using the HALO System
Radiofrequency Ablation: Stepwise circumferential and focal RFA of Barrett s s esophagus using the HALO System Used abbreviations BE: Barrett s esophagus EC: Early cancer ER: Endoscopic resection HGD:
More informationCitation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic management of Barrett s esophagus with dysplasia
UvA-DARE (Digital Academic Repository) Endoscopic management of Barrett s esophagus with dysplasia Phoa, Nadine Link to publication Citation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic
More informationBarrett s Esophagus. Radiofrequency Ablation with the HALO Technology A Reference Book
Radiofrequency Ablation with the HALO Technology A Reference Book 540 Oakmead Parkway, Sunnyvale, CA 94085 What is Barrett s esophagus? Barrett s esophagus is a change that occurs within the cellular lining
More informationCurrent Management: Role of Radiofrequency Ablation
Esophageal Adenocarcinoma And Barrett s Esophagus: Current Management: Role of Radiofrequency Ablation Ketan Kulkarni, MD Regional Gastroenterology Associates of Lancaster INTRODUCTION The prognosis of
More informationEndoscopic therapy of Barrett s esophagus Oliver Pech and Christian Ell
Endoscopic therapy of Barrett s esophagus Oliver Pech and Christian Ell Department of Internal Medicine 2, HSK Wiesbaden, Wiesbaden, Germany Correspondence to Oliver Pech, MD, PhD, Department of Gastroenterology,
More informationNew Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus
New Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus Prateek Sharma, MD Key Clinical Management Points: Endoscopic recognition of a columnar lined distal esophagus is crucial
More informationEvaluating Treatments of Barrett s Esophagus That Shows High-Grade Dysplasia
...PRESENTATIONS... Evaluating Treatments of Barrett s Esophagus That Shows High-Grade Dysplasia Based on a presentation by Bergein F. Overholt, MD Presentation Summary Thermal ablation and surgery are
More informationAdvances in endoscopic resection and radiofrequency ablation of early esophageal neoplasia van Vilsteren, F.G.I.
UvA-DARE (Digital Academic Repository) Advances in endoscopic resection and radiofrequency ablation of early esophageal neoplasia van Vilsteren, F.G.I. Link to publication Citation for published version
More informationAblation for Barrett s Esophagus: Burn or Freeze
Ablation for Barrett s Esophagus: Burn or Freeze John R. Saltzman MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Disclosures No relevant disclosures
More informationHow to remove BE cancer: EMR or ESD? Expected outcome
How to remove BE cancer: EMR or ESD? Expected outcome Presented by Horst Neuhaus Institution Dpt. of Gastroenterology Evangelisches Krankenhaus Düsseldorf, Germany Indications for endoscopic resection
More informationBarrett s esophagus. Barrett s neoplasia treatment trends
Options for endoscopic treatment of Barrett s esophagus Patrick S. Yachimski, MD MPH Director of Pancreatobiliary Endoscopy Assistant Professor of Medicine Division of Gastroenterology, Hepatology & Nutrition
More informationAdvances in endoscopic resection and radiofrequency ablation of early esophageal neoplasia van Vilsteren, F.G.I.
UvA-DARE (Digital Academic Repository) Advances in endoscopic resection and radiofrequency ablation of early esophageal neoplasia van Vilsteren, F.G.I. Link to publication Citation for published version
More informationGregory G. Ginsberg, M.D.
Radiofrequency Ablation for Barrett s Esophagus with HGD Gregory G. Ginsberg, M.D. Professor of Medicine University of Pennsylvania School of Medicine Abramson Cancer Center Gastroenterology Division Executive
More informationTreat Barrett s, Remove the Risk. HALO System
Treat Barrett s, Remove the Risk HALO System The HALO 360 System Advanced Ablation Technology for Barrett s Esophagus The HALO 360 System is designed to remove the Barrett s epithelium in a short, well-tolerated
More informationEndoscopic Management of Barrett s Esophagus
Endoscopic Management of Barrett s Esophagus Sammy Ho, MD Director of Pancreaticobiliary Services and Endoscopic Ultrasound Montefiore Medical Center Barrett s Esophagus Consequence of chronic GERD Mean
More informationBarrett Esophagus - RadioFrequency Ablation (BE-RFA) - Project manual + FAQ
Barrett Esophagus - RadioFrequency Ablation (BE-RFA) - Project manual + FAQ Table of contents 1 General project information...3 1.1 Inclusion criteria...3 1.2 Registration time points...3 1.3 Project variable
More informationBarrett s Esophagus: Old Dog, New Tricks
Barrett s Esophagus: Old Dog, New Tricks Stuart Jon Spechler, M.D. Chief, Division of Gastroenterology, VA North Texas Healthcare System; Co-Director, Esophageal Diseases Center, Professor of Medicine,
More informationBarrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI
Barrett s Esophagus Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI A 58 year-old, obese white man has had heartburn for more than 20 years. He read a magazine
More informationChanges to the diagnosis and management of Barrett s Oesophagus
Changes to the diagnosis and management of Barrett s Oesophagus A review of the new BSG and NICE guidelines and best practice Anjan Dhar DM, MD, FRCPE, AGAF, MBBS (Hons.), Cert. Med. Ed Senior Lecturer
More informationSixteen-year follow-up of Barrett s esophagus, endoscopically treated with argon plasma coagulation
Original Article Sixteen-year of Barrett s esophagus, endoscopically treated with argon plasma coagulation United European Gastroenterology Journal 2014, Vol. 2(5) 367 373! Author(s) 2014 Reprints and
More informationRadiofrequency ablation for early esophageal squamous cell neoplasia
Radiofrequency ablation for early esophageal squamous cell neoplasia Authors Y. M. Zhang 1, J. J. G. H. M. Bergman 2, B. Weusten 2, 3, S. M. Dawsey 4, D. E. Fleischer 5,N.Lu 6,S.He 1,G.Q.Wang 1 Institutions
More informationEradication of Barrett Esophagus with Early Neoplasia by Radiofrequency Ablation, with or without Endoscopic Resection
J Gastrointest Surg (2008) 12:1627 1637 DOI 10.1007/s11605-008-0629-1 Eradication of Barrett Esophagus with Early Neoplasia by Radiofrequency Ablation, with or without Endoscopic Resection Roos E. Pouw
More informationOpinion Statement. Esophagus (E Dellon, Section Editor)
Curr Treat Options Gastro (2016) 14:1 18 DOI 10.1007/s11938-016-0080-4 Esophagus (E Dellon, Section Editor) Current Controversies in Radiofrequency Ablation Therapy for Barrett s Esophagus Kamar Belghazi,
More informationPresent Day Management of Barrett s Esophagus
Slide 1 Present Day Management of Barrett s Esophagus Kinnari R. Kher, M.D. Slide 2 Goals Risk factors for development of Barrett s esophagus Risks for progression to Esophageal Adenocarcinoma Current
More informationHistopathology of Endoscopic Resection Specimens from Barrett's Esophagus
Histopathology of Endoscopic Resection Specimens from Barrett's Esophagus Br J Surg 38 oct. 1950 Definition of Barrett's esophagus A change in the esophageal epithelium of any length that can be recognized
More informationHow to perform: HALO 360 Radiofrequency Ablation of Barrett s s Esophagus
How to perform: HALO 360 Radiofrequency Ablation of Barrett s s Esophagus Used abbreviations BE: EID: ER: RFA: Barrett s esophagus Esophageal inner diameter Endoscopic resection Radiofrequency ablation
More informationManagement of Barrett s: From Imaging to Resection
Management of Barrett s: From Imaging to Resection Michael Wallace, MD, MPH, FACG Professor of Medicine Mayo Clinic Florida Goals of Endoscopic Evaluation in Barrett s Detect Barrett s and dysplasia Reduce/eliminate
More informationMedicare Advantage Medical Policy
Medicare Advantage Medical Policy Current Policy Effective Date: 1/1/18 Title: Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus Description/Background Barrett Esophagus and the
More informationLong-term recurrence of neoplasia and Barrett s epithelium after complete endoscopic resection
Editor s choice Scan to access more free content For numbered affiliations see end of article. Correspondence to Professor Thomas Rösch, Department of Interdisciplinary Endoscopy, University Hospital Hamburg-Eppendorf,
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett`s Esophagus. Original Policy Date
MP 2.01.52 Endoscopic Radiofrequency Ablation or Cryoablation for Barrett`s Esophagus Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett s Esophagus
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett s Esophagus Policy Number: 2.01.80 Last Review: 6/2018 Origination: 6/2012 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas
More informationLong-term recurrence of neoplasia and Barrett s epithelium after complete endoscopic resection
Editor s choice Scan to access more free content ORIGINAL ARTICLE Long-term recurrence of neoplasia and Barrett s epithelium after complete endoscopic resection Mario Anders, 1 Christina Bähr, 1 Muhammad
More informationAmerican Journal of Gastroenterology. Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma
Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma Journal: Manuscript ID: AJG-13-1412.R1 Manuscript Type: Letter to the Editor Keywords: Barrett-s esophagus, Esophagus, Endoscopy
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus Policy Number: Original Effective Date: MM.02.005 09/01/2010 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationJoel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery
Joel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery Norman Barrett (1950) described the esophagus as: that part of the foregut, distal to the cricopharyngeal sphincter, which is lined
More informationMANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018
MANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018 Sachin Wani Medical Director Esophageal and Gastric Center Division of Gastroenterology and Hepatology University of Colorado Anschutz Medical Campus DISCLOSURES
More informationCurrent Management of Low-Grade Dysplasia in Barrett Esophagus
Current Management of Low-Grade Dysplasia in Barrett Esophagus Gary W. Falk, MD, MS Dr Falk is a professor of medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School
More informationCryospray ablation using pressurized CO 2 for ablation of Barrett s esophagus with early neoplasia: early termination of a prospective series
E17 Cryospray ablation using pressurized CO 2 for ablation of Barrett s esophagus with early neoplasia: early termination of a prospective series Authors Romy E. Verbeek 1, Frank P. Vleggaar 1, Fiebo J.
More informationPatterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett s esophagus
Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett s esophagus Robert J. Korst, MD, a,b Sobeida Santana-Joseph, MSN, a,b John R. Rutledge, MAS,
More informationSection: Medicine Effective Date: July 15, 2015 Subsection: Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: June 2015 Page: 1 of 16 Cryoablation for Barrett s Esophagus Description Barrett s esophagus (BE) is a condition in which the normal squamous epithelium is replaced by specialized
More informationBarrett s Esophagus: Ablate Everyone?
Nicholas J. Shaheen, MD, MPH, FACG Barrett s Esophagus: Ablate Everyone? Nicholas J. Shaheen, MD, MPH, FACG Center for Esophageal Diseases and Swallowing University of North Carolina Greetings from UNC,
More informationRFA and Cyrotherapy for Esophageal Disease
RFA and Cyrotherapy for Esophageal Disease Daniel L. Miller MD Chief, General Thoracic Surgery WellStar Healthcare System/ Mayo Clinic Care Network Clinical Professor of Surgery Medical College of Georgia/
More informationBarrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD?
Barrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD? Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina 1 Outline What are the risks of progression
More informationRecurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett s esophagus may not be benign
THIEME E849 Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett s esophagus may not be benign Authors Georgina R. Cameron 1, 3, Paul
More informationGTS. Abbreviations and Acronyms BE ¼ Barrett s esophagus IM ¼ intestinal metaplasia NBI ¼ narrow band imaging RFA ¼ radiofrequency ablation
General Thoracic Surgery Korst et al Effect hiatal hernia size and columnar segment length on the success radirequency ablation for Barrett s esophagus: A single-center, phase II clinical trial Robert
More informationAGA SECTION. Gastroenterology 2016;150:
Gastroenterology 2016;150:1026 1030 April 2016 AGA Section 1027 Procedural intervention (3) Upper endoscopy indications 3 6 Non-response of symptoms to a 4 8 week empiric trial of twice-daily PPI Troublesome
More informationHistory. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management
Barrett s Esophagus: Controversy and Management History Norman Barrett (1950) Chronic Peptic Ulcer of the Oesophagus and Oesophagitis Allison and Johnstone (1953) The Oesophagus Lined with Gastric Mucous
More informationDefinition of GERD American College of Gastroenterology
Definition of GERD American College of Gastroenterology GERD is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus DeVault et al. Am J
More informationEditorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading?
Editorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading? Dr. Gaius Longcroft-Wheaton MB,BS, MD, MRCP(UK), MRCP(Gastro) Consultant gastroenterologist
More informationIs Radiofrequency Ablation Effective In Treating Barrett s Esophagus Patients with High-Grade Dysplasia?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Radiofrequency Ablation Effective
More informationEndoscopic resection (ER) is becoming increasingly established ALIMENTARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;11:630 635 ALIMENTARY TRACT Efficacy, Safety, and Long-term Results of Endoscopic Treatment for Early Stage Adenocarcinoma of the Esophagus With Low-risk sm1
More informationPopulations Interventions Comparators Outcomes Individuals: With Barrett esophagus with high-grade dysplasia
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett (20180) Medical Benefit Effective Date: 01/01/16 Next Review Date: 09/19 Preauthorization No Review Dates: 05/09, 03/10, 03/11, 03/12, 07/12,
More informationReview articles. Mario Rey Ferro, MD, 1 Raúl Eduardo Pinilla M, MD. 2
Review articles Complete cure of Barrett s Esophagus with low and high grade dysplasia through a combination of Focal Duette Endoscopic Mucosal Resection and Radiofrequency Ablation: Case report and literature
More informationEMR is not inferior to ESD for early Barrett s and EGJ neoplasia: An extensive review on outcome, recurrence and complication rates
E58 EMR is not inferior to ESD for early Barrett s and EGJ neoplasia: An extensive review on outcome, recurrence and complication rates Authors Institution Yoriaki Komeda, Marco Bruno, Arjun Koch Department
More informationVolumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment Barrett s esophagus
E318 Volumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment esophagus Authors Institution Arvind J. Trindade, Benley J. George, Joshua Berkowitz,
More informationThis medical position statement considers a series of
GASTROENTEROLOGY 2011;140:1084 1091 American Gastroenterological Association Medical Position Statement on the Management of Barrett s Esophagus The Institute Medical Position Panel consisted of the authors
More informationReview Article Outcomes of Radiofrequency Ablation for Dysplastic Barrett s Esophagus: A Comprehensive Review
Gastroenterology Research and Practice Volume 2016, Article ID 4249510, 8 pages http://dx.doi.org/10.1155/2016/4249510 Review Article Outcomes of Radiofrequency Ablation for Dysplastic Barrett s Esophagus:
More informationACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus
ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus Nicholas J. Shaheen, MD, MPH, FACG 1, Gary W. Falk, MD, MS, FACG 2, Prasad G. Iyer, MD, MSc, FACG 3 and Lauren Gerson, MD, MSc, FACG
More informationDisclosures. Gastroesophageal Reflux Disease. Gastroesophageal Reflux Disease
Kunal Jajoo, MD Brigham and Women s Hospital July 2012 Disclosures Spouse is a physician employed by Boston Scientific Corporation The content of this lecture equitably discusses products of multiple companies
More informationIn 1998, the American College of Gastroenterology issued ALIMENTARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1232 1236 ALIMENTARY TRACT Effects of Dropping the Requirement for Goblet Cells From the Diagnosis of Barrett s Esophagus MARIA WESTERHOFF,* LINDSEY HOVAN,
More informationHow to treat early gastric cancer? Endoscopy
How to treat early gastric cancer? Endoscopy Presented by Pierre H. Deprez Institution Cliniques universitaires Saint-Luc, Brussels Université catholique de Louvain 2 3 4 5 6 Background Diagnostic or therapeutic
More informationFaculty Disclosure. Objectives. State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) 24/11/2014
State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) Dr. Amy Morse November 2014 Faculty: Amy Morse Faculty Disclosure Relationships with commercial interests: Grants/Research
More informationDISCLOSURES. This program meets the requirements for GI specific Category 1 contact hours. M
DISCLOSURES Educational Dimensions is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center s Commission on Accreditation. Successful completion: Participants
More informationExtensive (8 to 12 cm 2 ) Noncircumferential Endoscopic Mucosal Resection for Early Esophageal Cancer
SECTION V: ESOPHAGUS MALIGNANT Extensive (8 to 12 cm 2 ) Noncircumferential Endoscopic Mucosal Resection for Early Esophageal Cancer Philippe Monnier, MD, Yves Jaquet, MD, Alexandre Radu, MD, Raphaelle
More informationThe incidence of esophageal adenocarcinoma is rising in the ENDOSCOPY CORNER
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:843 847 ENDOSCOPY CORNER Acetic Acid Spray Is an Effective Tool for the Endoscopic Detection of Neoplasia in Patients With Barrett s Esophagus GAIUS LONGCROFT
More informationLearning Objectives:
Crescent City GI Update 2018 Ochsner Clinic, NOLA Optimizing Endoscopic Evaluation of Barrett s Esophagus What Should I Do in My Practice? Gregory G. Ginsberg, M.D. Professor of Medicine University of
More informationManagement of Barrett s Esophagus. Case Presentation
Management of Barrett s Esophagus Lauren B. Gerson MD, MSc Associate Clinical Professor, UCSF Director of Clinical Research Gastroenterology Fellowship Program California Pacific Medical Center San Francisco,
More informationEndoscopic Submucosal Dissection ESD
Endoscopic Submucosal Dissection ESD Peter Draganov MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Florida Gastrointestinal Cancer Lesion that Can be Treated
More informationESD for EGC with undifferentiated histology
ESD for EGC with undifferentiated histology Jun Haeng Lee, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Biopsy: M/D adenocarcinoma ESD: SRC >>
More informationHow to stage early BE cancer - EUS or endoscopic removal?
How to stage early BE cancer - EUS or endoscopic removal? Presented by Bas Weusten Institution St. Antonius Hospital, Nieuwegein Academic Medical Center, Amsterdam case 56 y old female patient Lung transplant
More informationOutcomes in Patients Who Have Failed Endoscopic Therapy for Dysplastic Barrett s Metaplasia or Early Esophageal Cancer
Outcomes in Patients Who Have Failed Endoscopic Therapy for Dysplastic Barrett s Metaplasia or Early Esophageal Cancer Ben M. Hunt, MD, Brian E. Louie, MD, Drew B. Schembre, MD, Anthony G. Bohorfoush,
More informationSlide 1. Slide 2. Slide 3 DISCLOSURES EXPECTED OUTCOMES DIAGNOSIS AND TREATMENT
Slide 1 DIAGNOSIS AND TREATMENT 1 Slide 2 DISCLOSURES Successful completion: Participants must attend the entire program, including any resulting Q & A, and submit required documentation. Conflict of interest:
More informationNational Oesophago-Gastric Cancer Audit New Patient Registration sheet Patients with Oesophageal High Grade Glandular Dysplasia
National Oesophago-Gastric Cancer Audit New Patient Registration sheet Patients with Oesophageal High Grade Glandular Dysplasia Patient Details Surname: NHS number: Forename: Postcode: Sex: Male Female
More informationTreatment Strategy for Non-curative Resection of Early Gastric Cancer. Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea
Treatment Strategy for Non-curative Resection of Early Gastric Cancer Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea Classic EMR/ESD data analysis style Endoscopic resection
More informationCase Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
More informationSpeaker disclosure. Objectives. GERD: Who and When to Treat 7/21/2015
GERD: Who and When to Treat Eugenio J Hernandez, MD Gastrohealth, PL Assistant Professor of Clinical Medicine, FIU Herbert Wertheim School of Medicine Speaker disclosure I do not have any relevant commercial
More informationTreatment of High-Grade Dysplasia and Early Stage Esophageal Adenocarcinoma with an Endoscope: The Ultimate in Minimally Invasive, Curative Therapy
Curr Surg Rep (2014) 2:66 DOI 10.1007/s40137-014-0066-x ESOPHAGEAL/REFLUX SURGERY (SR DEMEESTER, SECTION EDITOR) Treatment of High-Grade Dysplasia and Early Stage Esophageal Adenocarcinoma with an Endoscope:
More informationThe normal esophagus is lined with squamous epithelium.
.. ALAN J. CAMERON, M.D. In Barrett's esophagus, the squamous lining of the lower esophagus is replaced by columnar epithelium. Barrett's esophagus is associated with gastroesophageal reflux and an increased
More informationBarrett's Esophagus: Sorting Out the Controversy
Barrett's Esophagus: Sorting Out the Controversy Learning Objectives 1. Identify the challenges in screening for Barrett s esophagus 2. Demonstrate comprehension of the risk of progression of Barrett s
More informationPhilip Chiu Associate Professor Department of Surgery, Prince of Wales Hospital The Chinese University of Hong Kong
Application of Chromoendoscopy, NBI and AFI in Esophagus why, who, and how? Philip Chiu Associate Professor Department of Surgery, Prince of Wales Hospital The Chinese University of Hong Kong Cancer of
More informationNonsurgical Management of Esophageal Cancer
8 Nonsurgical Management of Esophageal Cancer Malek M. Safa and Hassan K. Reda Dayton Cancer Center, Dayton, Ohio and University of Kentucky, Lexington, Kentucky, USA 1. Introduction In the recent past,
More informationRelative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia
Gut 2000;46:9 13 9 PAPERS Division of Gastroenterology, University of Kansas, VA Medical Center, Kansas City, Missouri, USA P Sharma A P Weston Department of Pathology, VA Medical Center, Kansas M Topalovski
More informationBarrett s Oesophagus Information Leaflet THE DIGESTIVE SYSTEM. gutscharity.org.
THE DIGESTIVE SYSTEM http://healthfavo.com/digestive-system-for-kids.html This factsheet is about Barrett s Oesophagus Barrett s Oesophagus is the term used for a pre-cancerous condition where the normal
More informationEndoscopic Therapy of Barrett s Esophagus and Esophageal Adenocarcinoma
Clinical imaging / therapy Endoscopic Therapy of Barrett s Esophagus and Esophageal Adenocarcinoma Marcel Tantau, Ofelia Mosteanu, Teodora Pop, Alina Tantau, Gabriela Mester University of Medicine and
More informationAdvanced endoscopic imaging of esophageal neoplasia; old looks and new visions Boerwinkel, David
UvA-DARE (Digital Academic Repository) Advanced endoscopic imaging of esophageal neoplasia; old looks and new visions Boerwinkel, David Link to publication Citation for published version (APA): Boerwinkel,
More informationThe Pathologist s Role in the Diagnosis and Management of Neoplasia in Barrett s Oesophagus Cian Muldoon, St. James s Hospital, Dublin
The Pathologist s Role in the Diagnosis and Management of Neoplasia in Barrett s Oesophagus Cian Muldoon, St. James s Hospital, Dublin 24.06.15 Norman Barrett Smiles [A brief digression - Chair becoming
More informationFrozen Section Analysis of Esophageal Endoscopic Mucosal Resection Specimens in the Real-Time Management of Barrett s Esophagus
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:173 178 Frozen Section Analysis of Esophageal Endoscopic Mucosal Resection Specimens in the Real-Time Management of Barrett s Esophagus GANAPATHY A. PRASAD,*
More informationNIH Public Access Author Manuscript Gastrointest Endosc. Author manuscript; available in PMC 2012 July 13.
NIH Public Access Author Manuscript Published in final edited form as: Gastrointest Endosc. 2012 July ; 76(1): 32 40. doi:10.1016/j.gie.2012.02.003. Characterization of buried glands before and after radiofrequency
More informationAre You Living with Barrett s Esophagus?
Are You Living with Barrett s Esophagus? Wouldn t you rather live without it? If you re living with Barrett s esophagus you are not alone. Barrett s esophagus is caused by the long-term exposure of your
More informationVital staining and Barrett s esophagus
Marcia Irene Canto, MD, MHS Baltimore, Maryland Vital staining or chromoendoscopy refers to staining of endoscopic tissue or topical application of chemical stains or pigments to alter tissue appearances
More informationRADIOFREQUENCY ABLATION OR CRYOABLATION FOR ESOPHAGEAL DISORDERS
DISORDERS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationQuiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False
Quiz 1 1. Which of the following are risk factors for esophagus cancer. a. Obesity b. Gastroesophageal reflux c. Smoking and Alcohol d. All of the above 2. Adenocarcinoma of the distal stomach has been
More informationDelayed Perforation Occurring after Endoscopic Submucosal Dissection for Early Gastric Cancer
CASE REPORT Clin Endosc 2015;48:251-255 Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.251 Open Access Delayed Perforation Occurring after Endoscopic Submucosal Dissection
More informationEMR, ESD and Beyond. Peter Draganov MD. Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Florida
EMR, ESD and Beyond Peter Draganov MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Florida Gastrointestinal Cancer Lesion that Can be Treated by Endoscopy
More informationCLINICAL TRIAL OUTCOMES: RADIOFREQUENCY ABLATION (RFA) FOR BARRETT S ESOPHAGUS
CLINICAL TRIAL OUTCOMES: RADIOFREQUENCY ABLATION (RFA) FOR BARRETT S ESOPHAGUS CLIN-0115 (Rev. D) Clinical Trial Outcomes of RFA for BE (Ref. ECO#12339) Page 1 of 82 T ABLE OF C O N T E N T S 1. INTRODUCTION...
More informationEndoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma
Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma J org Zehetner, MD, Steven R. DeMeester, MD, Jeffrey A. Hagen, MD, Shahin Ayazi, MD, Florian
More informationBarrett s Esophagus: Review of Diagnostic Issues and Pre- Neoplastic Lesions
Barrett s Esophagus: Review of Diagnostic Issues and Pre- Neoplastic Lesions Robert Odze, MD, FRCPC Chief, Gastrointestinal Pathology Associate Professor of Pathology Brigham and Women s Hospital Harvard
More informationBarrett s esophagus (BE) is a precancerous state
CLINICAL ALIMENTARY TRACT Gastroenterology 2017;153:681 688 Late Recurrence of Barrett s Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal
More informationmalignant polyp Daily Challenges in Digestive Endoscopy for Endoscopists and Endoscopy Nurses BSGIE Annual Meeting 18/09/2014 Mechelen
Plan Incidental finding of a malignant polyp 1. What is a polyp malignant? 2. Role of the pathologist and the endoscopist 3. Quantitative and qualitative risk assessment 4. How to decide what to do? Hubert
More information